S&P 500   4,274.04 (-0.72%)
DOW   33,980.32 (-0.50%)
QQQ   328.71 (-1.07%)
AAPL   174.77 (+1.01%)
MSFT   291.33 (-0.47%)
META   174.65 (-2.69%)
GOOGL   119.55 (-1.77%)
AMZN   142.08 (-1.86%)
TSLA   911.62 (-0.88%)
NVDA   183.48 (-2.81%)
NIO   20.10 (-3.87%)
BABA   89.77 (-3.11%)
AMD   98.30 (-1.90%)
MU   61.61 (-3.52%)
T   18.43 (-0.75%)
CGC   4.07 (+7.67%)
F   16.04 (-2.37%)
GE   79.89 (-1.46%)
DIS   122.79 (-1.74%)
AMC   20.92 (-15.68%)
PYPL   99.42 (-2.61%)
PFE   49.45 (-0.82%)
NFLX   241.03 (-1.90%)
S&P 500   4,274.04 (-0.72%)
DOW   33,980.32 (-0.50%)
QQQ   328.71 (-1.07%)
AAPL   174.77 (+1.01%)
MSFT   291.33 (-0.47%)
META   174.65 (-2.69%)
GOOGL   119.55 (-1.77%)
AMZN   142.08 (-1.86%)
TSLA   911.62 (-0.88%)
NVDA   183.48 (-2.81%)
NIO   20.10 (-3.87%)
BABA   89.77 (-3.11%)
AMD   98.30 (-1.90%)
MU   61.61 (-3.52%)
T   18.43 (-0.75%)
CGC   4.07 (+7.67%)
F   16.04 (-2.37%)
GE   79.89 (-1.46%)
DIS   122.79 (-1.74%)
AMC   20.92 (-15.68%)
PYPL   99.42 (-2.61%)
PFE   49.45 (-0.82%)
NFLX   241.03 (-1.90%)
S&P 500   4,274.04 (-0.72%)
DOW   33,980.32 (-0.50%)
QQQ   328.71 (-1.07%)
AAPL   174.77 (+1.01%)
MSFT   291.33 (-0.47%)
META   174.65 (-2.69%)
GOOGL   119.55 (-1.77%)
AMZN   142.08 (-1.86%)
TSLA   911.62 (-0.88%)
NVDA   183.48 (-2.81%)
NIO   20.10 (-3.87%)
BABA   89.77 (-3.11%)
AMD   98.30 (-1.90%)
MU   61.61 (-3.52%)
T   18.43 (-0.75%)
CGC   4.07 (+7.67%)
F   16.04 (-2.37%)
GE   79.89 (-1.46%)
DIS   122.79 (-1.74%)
AMC   20.92 (-15.68%)
PYPL   99.42 (-2.61%)
PFE   49.45 (-0.82%)
NFLX   241.03 (-1.90%)
S&P 500   4,274.04 (-0.72%)
DOW   33,980.32 (-0.50%)
QQQ   328.71 (-1.07%)
AAPL   174.77 (+1.01%)
MSFT   291.33 (-0.47%)
META   174.65 (-2.69%)
GOOGL   119.55 (-1.77%)
AMZN   142.08 (-1.86%)
TSLA   911.62 (-0.88%)
NVDA   183.48 (-2.81%)
NIO   20.10 (-3.87%)
BABA   89.77 (-3.11%)
AMD   98.30 (-1.90%)
MU   61.61 (-3.52%)
T   18.43 (-0.75%)
CGC   4.07 (+7.67%)
F   16.04 (-2.37%)
GE   79.89 (-1.46%)
DIS   122.79 (-1.74%)
AMC   20.92 (-15.68%)
PYPL   99.42 (-2.61%)
PFE   49.45 (-0.82%)
NFLX   241.03 (-1.90%)
NASDAQ:ADUS

Addus HomeCare - ADUS Stock Forecast, Price & News

$94.61
-1.24 (-1.29%)
(As of 08/17/2022 03:59 PM ET)
Add
Compare
Today's Range
$93.81
$94.87
50-Day Range
$75.30
$96.17
52-Week Range
$68.57
$108.11
Volume
1,085 shs
Average Volume
73,544 shs
Market Capitalization
$1.52 billion
P/E Ratio
34.28
Dividend Yield
N/A
Price Target
$110.40

Addus HomeCare MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
16.9% Upside
$110.40 Price Target
Short Interest
Bearish
1.91% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.49
Upright™ Environmental Score
News Sentiment
0.91mentions of Addus HomeCare in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$2.90 M Sold Last Quarter
Proj. Earnings Growth
15.41%
From $3.18 to $3.67 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.60 out of 5 stars

Medical Sector

142nd out of 1,122 stocks

Home Health Care Services Industry

6th out of 9 stocks

ADUS stock logo

About Addus HomeCare (NASDAQ:ADUS) Stock

Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. It operates through three segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living. This segment offers services that include assistance with bathing, grooming, oral care, feeding and dressing, medication reminders, meal planning and preparation, housekeeping, and transportation services. The Hospice segment provides palliative nursing care, social work, spiritual counseling, homemaker, and bereavement counseling services for people who are terminally ill, as well as related services for their families. The Home Health segment offers skilled nursing and physical, occupational, and speech therapy for the individuals who requires assistance during an illness or after hospitalization. The company's payor clients include federal, state, and local governmental agencies; managed care organizations; commercial insurers; and private individuals. As of December 31, 2021, the company served consumers through 206 offices located in 22 states. Addus HomeCare Corporation was founded in 1979 and is based in Frisco, Texas.

Addus HomeCare Price Performance

Shares of NASDAQ:ADUS opened at $95.85 on Wednesday. The business's 50 day moving average price is $87.75 and its two-hundred day moving average price is $84.14. Addus HomeCare has a twelve month low of $68.57 and a twelve month high of $108.11. The company has a market cap of $1.54 billion, a PE ratio of 34.73, a price-to-earnings-growth ratio of 2.55 and a beta of 0.85. The company has a quick ratio of 2.00, a current ratio of 2.00 and a debt-to-equity ratio of 0.33.

Addus HomeCare (NASDAQ:ADUS - Get Rating) last announced its earnings results on Monday, August 1st. The company reported $0.91 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.01). The company had revenue of $236.94 million for the quarter, compared to the consensus estimate of $238.40 million. Addus HomeCare had a return on equity of 8.63% and a net margin of 4.90%. The business's quarterly revenue was up 8.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.78 EPS. On average, analysts predict that Addus HomeCare will post 3.18 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on ADUS shares. Stephens reduced their price target on Addus HomeCare from $110.00 to $101.00 and set an "overweight" rating for the company in a research report on Tuesday, June 21st. Royal Bank of Canada reduced their price objective on shares of Addus HomeCare from $111.00 to $110.00 and set an "outperform" rating for the company in a research note on Wednesday, August 3rd. StockNews.com raised Addus HomeCare from a "buy" rating to a "strong-buy" rating in a research report on Friday, August 12th. Oppenheimer reduced their price target on Addus HomeCare from $135.00 to $130.00 and set an "outperform" rating for the company in a research report on Wednesday, August 3rd. Finally, Stifel Nicolaus assumed coverage on Addus HomeCare in a research report on Tuesday, June 28th. They set a "buy" rating and a $101.00 price target on the stock. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $110.40.

Insider Activity

In related news, EVP Sean Gaffney sold 10,000 shares of the business's stock in a transaction on Thursday, August 4th. The stock was sold at an average price of $95.00, for a total value of $950,000.00. Following the completion of the sale, the executive vice president now directly owns 14,413 shares in the company, valued at approximately $1,369,235. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, EVP Michael D. Wattenbarger sold 1,718 shares of the business's stock in a transaction that occurred on Tuesday, May 24th. The stock was sold at an average price of $85.00, for a total value of $146,030.00. Following the completion of the sale, the executive vice president now directly owns 7,012 shares in the company, valued at $596,020. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Sean Gaffney sold 10,000 shares of the firm's stock in a transaction on Thursday, August 4th. The stock was sold at an average price of $95.00, for a total value of $950,000.00. Following the transaction, the executive vice president now owns 14,413 shares in the company, valued at approximately $1,369,235. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 31,013 shares of company stock valued at $2,898,765. 4.50% of the stock is owned by insiders.

Receive ADUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Addus HomeCare and its competitors with MarketBeat's FREE daily newsletter.

ADUS Stock News Headlines

Addus HomeCare (NASDAQ:ADUS) PT Lowered to $130.00
Where Addus HomeCare Stands With Analysts
Addus HomeCare Corp - Stock Quote ADUS
4 Analysts Have This to Say About Addus HomeCare
See More Headlines
Receive ADUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Addus HomeCare and its competitors with MarketBeat's FREE daily newsletter.

ADUS Company Calendar

Last Earnings
8/01/2022
Today
8/17/2022
Next Earnings (Estimated)
11/07/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Home health care services
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ADUS
Employees
31,915
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$110.40
High Stock Price Forecast
$130.00
Low Stock Price Forecast
$101.00
Forecasted Upside/Downside
+16.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$45.13 million
Pretax Margin
6.67%

Debt

Sales & Book Value

Annual Sales
$864.50 million
Cash Flow
$4.11 per share
Book Value
$37.30 per share

Miscellaneous

Free Float
15,356,000
Market Cap
$1.52 billion
Optionable
Optionable
Beta
0.85














ADUS Stock - Frequently Asked Questions

Should I buy or sell Addus HomeCare stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Addus HomeCare in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ADUS shares.
View ADUS analyst ratings
or view top-rated stocks.

What is Addus HomeCare's stock price forecast for 2022?

5 brokerages have issued 12-month price objectives for Addus HomeCare's shares. Their ADUS share price forecasts range from $101.00 to $130.00. On average, they anticipate the company's stock price to reach $110.40 in the next twelve months. This suggests a possible upside of 15.2% from the stock's current price.
View analysts price targets for ADUS
or view top-rated stocks among Wall Street analysts.

How have ADUS shares performed in 2022?

Addus HomeCare's stock was trading at $93.51 at the beginning of 2022. Since then, ADUS stock has increased by 2.5% and is now trading at $95.85.
View the best growth stocks for 2022 here
.

When is Addus HomeCare's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 7th 2022.
View our ADUS earnings forecast
.

How were Addus HomeCare's earnings last quarter?

Addus HomeCare Co. (NASDAQ:ADUS) announced its quarterly earnings results on Monday, August, 1st. The company reported $0.91 earnings per share for the quarter, missing the consensus estimate of $0.92 by $0.01. The company earned $236.94 million during the quarter, compared to analyst estimates of $238.40 million. Addus HomeCare had a net margin of 4.90% and a trailing twelve-month return on equity of 8.63%. Addus HomeCare's revenue was up 8.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.78 earnings per share.

What is Dirk Allison's approval rating as Addus HomeCare's CEO?

91 employees have rated Addus HomeCare Chief Executive Officer Dirk Allison on Glassdoor.com. Dirk Allison has an approval rating of 51% among the company's employees. This puts Dirk Allison in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Addus HomeCare own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Addus HomeCare investors own include AbbVie (ABBV), Bank of America (BAC), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Verizon Communications (VZ), CVS Health (CVS), Pfizer (PFE), Ulta Beauty (ULTA), Cisco Systems (CSCO) and Walt Disney (DIS).

What is Addus HomeCare's stock symbol?

Addus HomeCare trades on the NASDAQ under the ticker symbol "ADUS."

Who are Addus HomeCare's major shareholders?

Addus HomeCare's stock is owned by many different institutional and retail investors. Top institutional shareholders include Principal Financial Group Inc. (3.76%), State Street Corp (3.47%), WCM Investment Management LLC (3.34%), Price T Rowe Associates Inc. MD (2.37%), Northern Trust Corp (1.82%) and Kennedy Capital Management Inc. (1.74%). Insiders that own company stock include Brian Poff, Darby Anderson, David W Tucker, Esteban Lopez, Laurie Manning, Mark L First, Michael D Wattenbarger, R Dirk Allison, Roberton James Stevenson, Sean Gaffney, Susan T Weaver and W Bradley Bickham.
View institutional ownership trends
.

How do I buy shares of Addus HomeCare?

Shares of ADUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Addus HomeCare's stock price today?

One share of ADUS stock can currently be purchased for approximately $95.85.

How much money does Addus HomeCare make?

Addus HomeCare (NASDAQ:ADUS) has a market capitalization of $1.54 billion and generates $864.50 million in revenue each year. The company earns $45.13 million in net income (profit) each year or $2.76 on an earnings per share basis.

How many employees does Addus HomeCare have?

The company employs 31,915 workers across the globe.

How can I contact Addus HomeCare?

Addus HomeCare's mailing address is 6801 GAYLORD PARKWAY, FRISCO TX, 75034. The official website for the company is www.addus.com. The company can be reached via phone at (469) 535-8200, via email at investorrelations@addus.com, or via fax at 630-487-2707.

This page (NASDAQ:ADUS) was last updated on 8/17/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.